A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

NCT00391222 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

585

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder

Interventions

DRUG: Olanzapine
DRUG: Placebo
DRUG: Risperidone Long Acting Injectable (LAI)

Sponsor

Janssen Pharmaceutica N.V., Belgium